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Background: The purpose of this study was to report initial results
of a phase I study using single-fraction stereotactic radiotherapy
(RT) in patients with inoperable lung tumors.
Methods: Eligible patients included those with inoperable T1-2N0
non-small cell lung cancer (NSCLC) or solitary lung metastases. Treat-
ments were delivered by means of the CyberKnife. All patients under-
went computed tomography-guided metallic fiducial placement in the
tumor for image-guided targeting. Nine to 20 patients were treated per
dose cohort starting at 15 Gy/fraction followed by dose escalation of 5
to 10 Gy to a maximal dose of 30 Gy/fraction. A minimal 3-month
period was required between each dose level to monitor toxicity.
Results: Thirty-two patients (21 NSCLC and 11 metastatic tumors)
were enrolled. At 25 Gy, pulmonary toxicity was noted in patients
with prior pulmonary RT and treatment volumes greater than 50 cc;
therefore, dose escalation to 30 Gy was applied only to unirradiated
patients and treatment volume less than 50 cc. Ten patients received
doses less than 20 Gy, 20 received 25 Gy, and two received 30 Gy.
RT-related complications were noted for doses greater than 25 Gy and
included four cases of grade 2 to 3 pneumonitis, one pleural effusion,
and three possible treatment-related deaths. The 1-year freedom from
local progression was 91% for dose greater than 20 Gy and 54% for
dose less than 20 Gy in NSCLC (p  0.03). NSCLC patients had
significantly better freedom from relapse (p  0.003) and borderline
higher survival than those with metastatic tumors (p  0.07).
Conclusions: Single-fraction stereotactic RT is feasible for selected
patients with lung tumors. For those with prior thoracic RT, 25 Gy
may be too toxic. Higher dose was associated with improved local
control. Longer follow-up is necessary to determine the treatment
efficacy and toxicity.
Key Words: Stereotactic radiotherapy, CyberKnife, Single fraction,
Extracranial, Lung cancer, Solitary metastasis.
(J Thorac Oncol. 2006;1: 802–809)
A widely accepted management for stage I (T1-2N0) non-small cell lung cancer (NSCLC) or solitary metastases to
the lung is surgical resection. However, some patients are not
eligible for surgery because of poor lung function, low
performance status, or significant comorbidities. Convention-
ally fractionated radiotherapy provides a reasonable alterna-
tive to surgery in some patients. The outcome after conven-
tional radiotherapy, although potentially amplified by treatment
selection biases, is poor compared with surgery, with local
control rates ranging from 40 to 70% and 5-year survival
ranging from 10 to 30%.1–3 In addition, conventionally frac-
tionated radiotherapy is associated with the inconvenience of
a protracted treatment course up to 10 weeks in cases of dose
escalation.
Stereotactic radiosurgery for intracranial tumors has
been widely available since 1990. In 1995, when Blomgren et
al. introduced a new stereotactic treatment technique for lung
and liver tumors using a stereotactic body frame, the tech-
nique was expanded to include extracranial tumors.4 Results
using hypofractionated stereotactic radiotherapy (SRT) for
lung tumors have been promising.5–8 Onishi et al. performed
a retrospective multi-institutional analysis of 245 Japanese
patients treated with hypofractionated SRT and reported an
impressively low overall local recurrence rate of 8% for
patients who received a biologic equivalent dose (BED)
greater than 100 Gy and 26% for those with a BED less than
100 Gy.9 In addition, the 3-year overall survival rate for
medically operable patients who received a BED greater than
100 Gy was excellent at 88%. Based on these encouraging
data, we initiated a phase I dose-escalation study using
single-fraction SRT delivered by means of the CyberKnife
stereotactic radiosurgery system (Accuray, Inc., Sunnyvale,
CA) in patients who were not candidates for surgical resec-
tion of either stage I NSCLC or solitary pulmonary metasta-
ses. In this article, we report the preliminary results of this
dose-escalation study.
PATIENTS AND METHODS
Between May of 2000 and April of 2005, 33 patients
with either stage I NSCLC or solitary pulmonary metastases
were enrolled in the study. One NSCLC patient was found to
be ineligible because of chest wall invasion; therefore, 32
patients formed the study cohort. All patients signed an
informed consent approved by the institutional review board.
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Eligibility criteria include tumor less than or equal to 5.0 cm
at the time of evaluation, age older than 18 years, Eastern
Cooperative Oncology Group performance status of 0 to 2,
histologic confirmation of malignancy, inoperable T1–2
NSCLC, or metastatic diseases. Patients were considered
inoperable when tumors were unresectable by radiographic
criteria (such as direct invasion of the mediastinum for
metastatic tumors); by virtue of poor pulmonary function,
excessive medical comorbidities, or patient refusal to un-
dergo surgery; or by prior operative findings. All patients
were evaluated by a multidisciplinary team (thoracic surgery,
radiation oncology, and medical oncology) before entry into
the protocol.
Pretreatment staging studies included serum tumor
markers (if available), chest computed tomography (CT) in
all patients, and fluorodeoxyglucose (FDG) positron emission
tomography (PET) scans in 29 patients since 2001. For
targeting purposes, all patients had three to five gold fiducials
implanted into the tumor by means of CT guidance. Only one
single fiducial (from four placed in one patient) was noted to
fall out between the time of fiducial placement and the
treatment-planning CT. A vacuum-set moldable Styrofoam
immobilization cushion (Vac Bag, MedTech, South Plains-
field, NJ) was custom-formed for each patient 7 to 14 days
after fiducial placement. Subsequently, a breathhold chest CT
scan (1.25-mm slice thickness, 30 patients), or more recently
a four-dimensional CT scan (three patients), was performed
with the patient in the treatment position. Together, a thoracic
surgeon and a radiation oncologist delineated the tumor
volume on the lung window of the planning CT scan. A
2-mm planning target volume (PTV) margin was initially
used for the first 10 patients; however, on analysis, the
maximal intrafraction fiducial motion was determined to be 5
mm; therefore, a 5-mm circumferential margin was added for
the subsequent 22 patients to account for intrafraction tumor
motion.10 A radiosurgical treatment plan was generated based
on tumor location and geometry. Figure 1 shows an example
of an SRT plan for a patient with NSCLC. Doses were
prescribed to ensure that more than 95% of the PTV was
covered within the prescribed isodose line. Specified dose
limits to normal structures were as follows: 8-Gy maximal
point dose to the spinal cord, less than or equal to 5 Gy to
two-thirds of the total lung volume; less than or equal to 10
Gy to 50% of the total heart volume; 20-Gy maximal point
dose and less than or equal to 10 Gy to 50% of the total
esophageal volume; 10-Gy maximal point dose to the bra-
chial plexus, and less than or equal to 7.5 Gy to 50% of the
total liver volume. All patients were treated within 2 weeks of
their planning CT scan and within 4 weeks of enrollment on
the protocol.
All treatments were administered as a single fraction.
The previously described breathhold technique was used in
the first 23 patients.10,11 Patients were coached to hold their
breath in mid to late expiratory phase for 15 to 20 seconds.
The fiducial positions were tracked by orthogonal x-ray
image pairs at each treatment beam position to ensure repro-
ducibility. Previous studies from our institution revealed that
fiducial position in the lung tumors varied by an average of
1.05 mm per axis (range, 0–5 mm).10 The overall treatment
time for the breathhold technique ranged from 2 to 6 hours;
the majority of the patients completed treatment in less than
3 hours. The last 10 patients were treated using the Syn-
chrony (Accuray) respiratory tracking system.12 The Syn-
chrony system uses an infrared camera that continuously
tracks the position of three external light-emitting diode
markers placed on the patient’s chest wall. Multiple images
of the internal fiducials are acquired throughout the respira-
tory cycle before each treatment session using the orthogonal
x-ray imagers, and a correlation model is built to predict
internal marker position from the continuously tracked exter-
nal markers. The position of the linear accelerator is then
adjusted accordingly by the robotic arm in real time. Between
each beam position, a new orthogonal image pair is acquired and
the correlation model is updated. If the recorded correlation error
is greater than a given threshold, treatment is temporarily
stopped and a new correlation model is built. The average
treatment time using the Synchrony system was 1.5 hours.
The primary endpoint of this phase I study was to
identify the maximum-tolerated dose (MTD) using single-
fraction SRT in patients with lung tumor based on acute
radiation treatment-related toxicities observed within 3
months of therapy. Secondary endpoints included the deter-
mination of the incidence and profile of subacute toxicity, the
local control rate, and the pattern of failure in these patients.
FIGURE 1. (A) An example of the
dose coverage on an axial CT im-
age in a patient with a T2N0
NSCLC. The green line represents
the 25-Gy dose prescribed to the
64% isodose line. (B) CT scan at
6-month follow-up shows a com-
plete response, with posttreatment
interstitial lung changes.
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Initially, four dose levels were planned: 15, 20, 25, and 30
Gy, with nine to 10 patients per dose level. A minimum of 90
days was required between the treatment of the last patient at
a given dose and the first patient at the next dose level to
permit sufficient time to observe all acute toxicity, defined as
within 3 months of SRT. The MTD was defined as four or
more patients at a given dose level experiencing grade III or
greater toxicity (Common Toxicity Scale, from the National
Cancer Institute, version 3.0). During our dose-escalation
process, however, a separate dose-escalation study was pub-
lished showing that it was safe to deliver 60 Gy in three
fractions of 20 Gy/fraction to patients with stage I NSCLC.6
Therefore, we elected to bypass the 20-Gy dose level and
proceeded directly to 25 Gy after safety had been established
for the 15-Gy dose level. In addition, during the dose-
escalation portion, we noted excessive late toxicity in patients
who had received prior thoracic radiotherapy at the dose of 25
Gy. As such, the protocol was amended to proceed with dose
escalation to 30 Gy only in patients with tumor volume less
than 50 cc and no prior thoracic radiotherapy. The BED was
calculated using the following formula: BED  nd[1 
d/(/)] where n  number of fractions, d  fraction dose,
and / is assumed to be 10.
RESULTS
Patient Characteristics
Thirty-two patients (20 primary NSCLC and 12 recur-
rent/metastatic tumors) formed the study cohort. Patient and
tumor characteristics are shown in Table 1. The median age
was 73 years (range, 22–83 years). Maximal tumor diameter
ranged from 2 to 6.2 cm; tumor volume ranged from 2.0 to
113 cc (median, 17.3 cc). One patient had a 5-cm tumor at the
entrance into the study, but the tumor had grown to 6.2 cm
after fiducial placement; the remaining patients had maximal
tumor diameter less than 5 cm. Nine patients received 15 Gy,
one received 20 Gy, 20 received 25 Gy, and two received 30
Gy. Treatment details are shown in Table 2. A BED greater
than 100 Gy at the isocenter (assuming a / of 10) was
achieved in 73% of the patients and a BED greater than 50 Gy
at the periphery was achieved in 62% of the patients. The
median follow-up for living patients was 18 months (range,
9–32 months). Only two patients were lost to follow-up, one
at 9 months at the time of local and distant relapse and one at
32 months without evidence of disease.
Posttreatment Lung Function and
Treatment-Related Toxicity
The only significant acute treatment toxicity was re-
lated to fiducial placement. Six patients (19%) developed
pneumothorax, three (9%) of which required chest-tube
placement (24–48 hours). One patient was hospitalized over-
night for mild chronic obstructive pulmonary disease exac-
erbation after the fiducial placement. Ten patients complained
of either fatigue (1–2 weeks in duration) or a slight increase
in shortness of breath within 3 months of treatment, but none
required institution of steroid therapy or adjustment of their
supplemental oxygen requirement. Pretreatment forced expi-
ratory volume in 1 second, forced-vital capacity, and diffu-
sion capacity for carbon monoxide were available for all
patients, and the 3-month posttreatment forced expiratory
volume in 1 second and forced-vital capacity were available
in 17 patients and the diffusion capacity for carbon monoxide
was available in 10 patients. There was no significant change
in these three parameters in association with treatment during
the first 3 months.
Late treatment-related toxicities are shown in Table 3.
All toxicities occurred at doses greater than 20 Gy. The
majority of the toxicities (five of eight) were found in central
TABLE 1. Patient and Tumor Characteristics
Parameter No. (%)
Age (median, 72 yr; range, 22–83 yr)
70 14 (44)
70 18 (56)
Gender
Female 19 (59)
Male 13 (41)
Laterality
Left 13 (41)
Right 19 (59)
Maximal diameter (median, 3.9 cm;
range, 2–6.2 cm)
3 cm 8 (25)
3 cm 24 (75)
Tumor volume (median, 17.1 cc;
range, 2.0–103 cc)
15 cc 15 (49)
15 cc 17 (51)
Treatment volume (median, 33.5;
range, 6.8–113)
30 13 (31)
30 19 (69)
Tumor type
NSCLC 20 (62.5), 6 T1, 14 T2
Metastatic/recurrent 12 (37.5)
Histology
Adenocarcinoma 20 (63)
Squamous 7 (22)
NSCLC 2 (6)
Sarcoma 2 (6)
HCC 1 (3)
Prior lung resection
None 22 (69)
Wedge resection 1 (3)
Lobectomy 8 (25)
Pneumonectomy 1 (3)
Prior thoracic RT
No 26 (81)
Yes 6 (19)
Prior systemic therapy
None 22 (69)
Chemotherapy 9 (28)
Hormone 1 (3)
NSCLC, non-small cell lung cancer; HCC, hepatocellular carcinoma; RT, radiation
therapy.
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tumors and in patients with PTV greater than 50 cc. Most
toxicity occurred 5 to 6 months after SRT. There were four
patients with grade 2 to 3 pneumonitis; one occurred after the
initiation of chemotherapy for progressive metastatic colo-
rectal cancer. One patient developed a small pleural effusion
with COPD exacerbation that spontaneously resolved. There
were three deaths after treatment, all in patients who received
chemotherapy either before or after SRT. Two of the three
patients had also received prior thoracic radiation. The first
patient was previously treated with thoracic radiotherapy and
chemotherapy for a midesophageal carcinoma. She then de-
veloped a T2N0 apical NSCLC, treated with SRT. She
subsequently developed a pleural effusion and pnemonitic
changes on CT scans. FDG-PET scan revealed hypermetab-
olism both in the effusion and in the contralateral lung. The
initial pleural fluid cytologic examination was negative for
malignancy. The patient refused further workup and opted for
home hospice care. The second patient had a prior right
pneumonectomy for a previous T4 lung cancer and also
received prior fractionated RT for a left lower lobe metasta-
sis. He was treated with 25-Gy SRT for a hilar recurrence.
Despite a radiographic complete response (CR), his medical
oncologist initiated adjuvant gemcitabine-based chemother-
apy 2 months after SRT. Following the second cycle of
gemcitabine, he developed a pulmonary embolism and signs
and symptoms consistent with radiation pneumonitis. He
ultimately died as a result of pulmonary complications. The
last patient received SRT for a T2N0 NSCLC. Although CT
scan showed stable tumor, serial FDG-PET scans showed
resolution of FDG uptake. He was started on adjuvant che-
motherapy with carboplatin and paclitaxel 3 months after his
SRT for radiographically stable disease. When his chemo-
therapy was switched to gemcitabine because of peripheral
neuropathy from the second cycle of paclitaxel, he developed
a tracheoesophageal fistula followed by a fatal hemoptysis
from a tracheovascular fistula. Postmortem studies confirmed
the fistula without evidence of cancer.
Treatment Outcomes
Table 4 shows treatment response by dose levels. Re-
sponse was defined using the pre-RECIST criteria.13 A CR
represents complete disappearance of the treated tumor; a
partial response represents radiographic partial regression
greater than 50% in the overall tumor bidimensional area
using the largest tumor diameters; a minor response repre-
sents radiographic partial regression of the overall tumor
bidimensional area between 25 and 50%, and stable disease
TABLE 3. Observed Radiation-Related Toxicities and Treatment Received
Dose (Gy)
PTV
Volume (cc) Location
Time to
Toxicity (mo)
Prior
Thoracic RT
Before or After RT
Chemotherapy Toxicity Grade
25 20.3 Peripheral 3 None None Pleural effusion 2
25 20.2 Peripheral 6 None None Pneumonitis 3
25 74.3 Central 6 None Carboplatin, paclitaxel,
gemcitabine
Tracheoesophageal fistula 5
25 69.6 Central 3 None FOLFOX, FOLFIRI,
bevacizumab
Pneumonitis 2
25 61.9 Central 6 None Megestrol acetate Pneumonitis, atrial
fibrillation
2
25 86.3 Central 5 Yes Cisplatin, 5-flourouracil Pneumonitis, pleural
effusion (vs.
recurrence)
5
25 36.6 Central 5 Yes Gemcitabine, gefitinib,
trastuzumab
PE and recalled
pneumonitis
5
30 50.6 Peripheral 5 None None Pneumonitis 2
PTV, planning target volume; FOLFOX, 5-fluorouracil (5-FU), leucovorin, oxaliplatin; FOLFIRI, 5-FU, leucovorin, irinotecan; PE, pulmonary embolism.
TABLE 2. Treatment Characteristics
Parameter No. (%)
Dose median IDL, 72% (range, 60–80%)
15 Gy 9 (28)
20 Gy 1 (3)
25 Gy 20 (63)
30 Gy 2 (6)
Dmax median, 35.7 Gy; (range, 18.4–42.9 Gy)
20 7 (22)
20.1–30 3 (9)
30.1–40 18 (56)
40 4 (13)
Isocenter BED (/  10)
100 Gy 9 (28)
101–200 Gy 19 (59)
200 Gy 4 (13)
Peripheral BED (/  10)
50 Gy 9 (28)
50 Gy 23 (62)
Collimator size (median No. of beams, 117;
range, 81–225)
20 mm 3 (9)
25–30 mm 10 (31.5)
35–40 mm 10 (31.5)
45–50 mm 9 (28)
IDL, isodose line; BED, biologic equivalent dose.
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represents a less than 25% decrease or increase in the tumor
bidimensional area. CT scans were used to determine radio-
graphic responses. The response rates (CR  partial re-
sponse) were similar across the dose levels: 60% (six of 10)
for 15 Gy, 65% (13 of 20) for 25 Gy, and 100% (two of two)
for 30 Gy. However, there was a higher CR rate for dose
greater than 20 Gy compared with dose less than 20 Gy (10%
versus 57%; p  0.21, Fisher’s exact test). Figure 1 shows a
CT image of a patient with a CR and posttreatment changes
after SRT. Metabolic responses by FDG-PET scans at 2 to 6
months after treatment were documented in 14 patients but
were not used to score responses. Six patients had complete
resolution of metabolic activity, four had partial or near-
complete resolution, and four had increased activity. Full
concordance between PET and CT changes was noted only
for the four patients with progressive local disease.
Local relapse and other relapse by dose levels are
shown in Table 5. Most local relapses for primary NSCLC
occurred with doses less than 20 Gy. There was no local
relapse in the six patients with T1 tumors and only one local
failure in seven patients treated with dose greater than 25 Gy.
The 1-year Kaplan-Meier freedom from local relapse (FFLR)
estimate was 100% for T1 tumors (n 5), 83% for T2 tumors
treated with doses greater than 20 Gy (n  7), and 51% for
T2 tumors treated with doses less than 20 Gy (n 7) (Figure 2).
When all primary NSCLC patients were grouped together, a
higher 1-year FFLR rate was noted for higher doses (91% for
dose 20 Gy versus 51% for dose 20 Gy, p  0.03).
Figure 3 shows FFLR by tumor type. There were
significantly higher local control rates for NSCLC when
compared with metastatic tumors (p  0.03). This effect was
more pronounced in the subset of patients who received doses
greater than 20 Gy. The 1-year FFLR was 92% for primary
NSCLC patients compared with 44% for metastatic patients
when doses were greater than 20 Gy (p  0.003). As shown
in Table 5, metastatic tumors treated at the 25-Gy dose level
generally had larger tumor volumes than those of T2 primary
NSCLC treated at the same dose level (median volume of
27 cc versus 9.4 cc); this volume discrepancy may partially
explain the difference in local control. There were too few
patients at the 30-Gy dose level for us to make any definitive
statements.
TABLE 4. Response by Radiation Dose
No. of
Patients
Response
Dose CR PR MR SD
20 Gy 10 1 5 3 1
25 Gy 20 8 5* 4 3*
30 Gy 2 0 2 0 0
Total 32 9 12 7 4
*One patient in each group achieved complete metabolic response on PET scans.
CR, complete response; PR, partial response; MR, minor response; SD, stable disease.
TABLE 5. Local Relapse by Tumor Type (Primary NSCLC versus Metastatic/Recurrent) and Dose Level
Local Relapse (%) Nodal and/or Distant Metastasis (%)
Primary NSCLC
Metastatic/Recurrent
Tumors
Primary NSCLC
Metastatic/Recurrent
TumorsDose T1 T2 T1 T2
20 Gy 4/7 (57)* 1/3 (33) 4/7* (57) 2/3 (66)
Tumor volume (cc) Median (Range) 40 (15–113) 13 (13–63)
25 Gy 0/5 (0) 0/6 (0) 4/9 (44) 2/5 (40) 2/7 (29) 7/9 (78)
Tumor volume (cc) Median (Range) 4.4 (2.0–7.9) 9.4 (5.2–53) 27 (6.3–63.6)
30 Gy 0/1 (0) 1/1 (100) 1/1 0/1
Tumor volume (cc) 7 34.8
*All patients were found to have concurrent local relapse and distant metastases. NSCLC, non-small cell lung cancer.
FIGURE 2. Freedom from local relapse by T stage and pre-
scribed dose for NSCLC.
FIGURE 3. Freedom from local relapse by tumor type: pri-
mary NSCLC versus metastatic/recurrent tumors.
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Patients with primary NSCLC had significantly higher
freedom from relapse and a trend for better overall survival
(Figure 4) when compared with those treated for metastatic
disease. The 1-year freedom from relapse was 67% for
NSCLC versus 25% for metastatic patients (p  0.003). The
1-year overall survival was 85% for NSCLC versus 56% for
metastatic patients (p  0.07).
DISCUSSION
This study represents preliminary results of a phase I
dose-escalation study evaluating the toxicity of single-frac-
tion SRT in patients who are not surgical candidates for either
stage I NSCLC or solitary metastases. The main rationale for
using single-fraction treatment was the ease of radiation
delivery, as these treatments often required hours to deliver.
In addition, for metastatic tumors, the single-fraction delivery
replicates the approach that has been successfully used for the
treatment of brain metastases over the past two decades.
We observed two factors that appeared to be associated
with treatment-related toxicity: a history of prior thoracic
radiotherapy and chemotherapy use, either before or after
SRT. In terms of radiotherapy, we found that the 25-Gy dose
in a single fraction resulted in significant toxicity in patients
who had received prior thoracic radiotherapy. Two of our
presumed treatment-related deaths were in such patients.
Therefore, we revised our dose-escalation criteria to proceed
to the 30-Gy dose only in previously unirradiated patients
with treatment volume less than 50 cc. The revised criteria
limited the number of patients at the 30-Gy dose level.
The other factor that appeared to be associated with
increased treatment-related toxicity was the use of prior or
posttreatment chemotherapy. As part of the protocol, the
patients were not allowed to receive any chemotherapy within
2 weeks of radiation treatment, although chemotherapy
greater than 1 month after radiotherapy was allowed at the
discretion of the treating oncologist. As shown in Table 3, all
three patients with treatment-related deaths received chemo-
therapy either before or after SRT, and in two, the toxicity
was possibly triggered by gemcitabine-based chemotherapy
delivered up to 6 months after completion of SRT. Therefore,
in the era when adjuvant chemotherapy is commonly advo-
cated for patients with stage Ib (T2N0) NSCLC based on
favorable survival outcomes in surgically treated patients, we
would caution against the routine use of adjuvant chemother-
apy, specifically, adjuvant gemcitabine-based chemotherapy,
with this SRT regimen outside the confines of a research
protocol.14–16 Recalled radiation-related toxicity with the ad-
ministration of gemcitabine, though uncommon, has been
reported in the literature for lung, breast, and pancreatic
cancers and can occur as late as 6 months after radiation
treatment.17,18 In addition, these recalled reactions may be
further exacerbated by large dose per fraction. The use of
adjuvant chemotherapy with large-fraction SRT needs to be
further evaluated in future studies.
The majority of the patients with grade 2 or greater
toxicity (five of eight) (Table 3) had either centrally located
tumors and/or tumors with treatment volumes greater than
50 cc. This is consistent with the data reported by Timmer-
man et al., who noted a higher risk of late grade 3 to 5 toxicity
in patients with central tumors compared with those with
peripheral tumors.19 Based on these data, we are considering
revised fractionation schedules of 60 Gy in three fractions for
peripheral tumors and either 48 Gy in four fractions or 50 Gy
in five fractions for central tumors. These fractionation reg-
imens have yielded promising results in several Japanese
studies.9,20
Another important feature of the observed pulmonary
toxicities in this study was that they occurred late in the
course of follow-up. All but one of our radiation-related
complications occurred more than 3 months after radiation
treatment, beyond the time window required for dose esca-
lation in this and other studies.21 These data indicated that
long-term follow-up and large patient cohorts are needed to
optimally determine the dose-limiting toxicity and to identify
the MTDs for SRT of lung tumor.
In terms of a dose-response relationship in patients with
NSCLC, our data confirm those of others.9,21,22 Onishi et al.
reported a significantly higher rate of local recurrence in
patients treated with central tumor BED of less than 100 Gy
compared with those with a BED greater than 100 Gy.9 Wulf
et al. performed a retrospective evaluation of 92 pulmonary
tumors treated at their institution with SRT and identified the
dose at the PTV margin as the only significant parameter for
local control on multivariate analyses.22 Our data suggest that
local control is related to the prescribed doses at the tumor
periphery and are consistent with the findings by Wulf et al.22
When we analyzed local control by central tumor BED using
the dividing point of 100 Gy as suggested by Onishi et al., we
did not see a difference in the local tumor control rates (data
not shown, p  0.05). These results suggested that minimum
tumor doses are more important for local control than the
central tumor doses.
With regard to the dose-rate effect, there are no clinical
data to suggest an adverse impact on tumor control when
large single-fraction radiation is delivered over 3 to 5 hours as
opposed to a few minutes. Cell culture experiments suggest
that sublethal damage repair is more prevalent at lower dose
rates; however, this effect is partially mitigated by cell cycle
redistribution. These laboratory observations have not been
substantiated by clinical studies, particularly in the 3- to
5-hour time range. Some retrospective analyses of head and
FIGURE 4. Overall survival by tumor type: primary NSCLC
versus metastatic/recurrent tumors.
Journal of Thoracic Oncology • Volume 1, Number 8, October 2006 Stereotactic Radiotherapy for Lung Cancers
Copyright © 2006 by the International Association for the Study of Lung Cancer 807
neck cancer patients treated with interstitial iridium-192 im-
plants suggested a higher local failure rate in patients treated
with a lower dose rate (0.5 Gy/hour) and a lower total dose
(60 Gy).23 In these studies, it is important to note that these
effects were reported when brachytherapy was administered
over a period of days, not hours. There are no data that allow
us to extrapolate these effects to a 3- to 5-hour treatment.
Unlike others, however, we noted a higher local control
rate for NSCLC tumors when compared with metastatic
lesions. However, the two patient populations are not com-
parable, and these results should be interpreted with caution.
Although patients with primary NSCLC had not received
prior therapy, most of the patients with metastatic/recurrent
tumors were heavily pretreated with chemotherapy, and sev-
eral also had received prior thoracic radiotherapy. In addition,
the difference in the local control rates between NSCLC and
metastatic/recurrent tumors was dominated by the 25-Gy
dose group, where the tumor volumes were relatively larger
for metastatic/recurrent tumors than for NSCLC tumors. The
mean and median tumor volumes were 21 and 9.4 cc, respec-
tively, for NSCLC and 28 and 27 cc, respectively, for meta-
static tumors (p 0.06 using the Mann-Whitney rank test). In
addition, microenvironmental factors such as tumor hypoxia,
which has been shown to be associated with metastasis, are
more likely to affect local control adversely for a single-
fraction regimen such as ours rather than for a more pro-
tracted fractionated regimen.24–26 Our future strategy for
metastatic tumors is to increase the minimal tumor BED by
adopting a fractionated approach such as 48 Gy in four
fractions as used by Nagata et al.20 In addition, we will
explore hypoxia imaging and the use of a hypoxic cell toxin
or sensitizer in these tumors.
As demonstrated by others, we found that the most
common sites of failure for both NSCLC and metastatic
patients treated with higher doses were distant and/or regional
lymph nodes.21 In addition, randomized studies have shown a
survival benefit for NSCLC patients with stage IB to II
tumors treated with adjuvant chemotherapy after surgery
when compared with those treated with surgery alone.14–16
Based on these data, there has been an impetus to add adjuvant
systemic therapy to SRT, specifically, in patients with large T2
tumors or metastatic disease. The strategy of how best to
integrate systemic treatment with SRT, the optimal chemo-
therapeutic agents, and dose schedule is largely unknown. In
addition, the use of adjuvant chemotherapy can result in
significant recalled toxicity, as experienced by two of our
patients. Therefore, the use of adjuvant chemotherapy in
conjunction with SRT for NSCLC should be used with
caution and preferentially on study. An ongoing trial at the
University of Indiana will possibly shed some light on this
important issue.21
CONCLUSIONS
Limitations of this study include the heterogeneity of
enrolled patients in terms of tumor types, pre- and post-SRT
therapy, and variation in treatment techniques (breathholding
versus tracking) and tumor margins during the course of the
study. However, it establishes the feasibility of delivering
single-fraction SRT in patients with thoracic malignancy with
the CyberKnife and provides relevant clinical information in
this setting. Our phase I dose-escalation study shows that 25
Gy in a single fraction is well tolerated in previously un-
treated patients but may be too toxic in patients who have
previously received thoracic irradiation and large central
tumors. We are currently completing our 30-Gy dose cohort,
but future strategies will focus on increased fractionation and
integration of systemic therapy. Continuation of the study and
long-term follow-up are necessary to determine the overall
treatment efficacy and toxicity.
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